Outcomes and endpoints in cancer trials: Bridging the divide

Michelle K. Wilson, Deborah Collyar, Diana T. Chingos, Michael Friedlander, Tony W. Ho, Katherine Karakasis, Stan Kaye, Mahesh K B Parmar, Matthew R. Sydes, Ian F. Tannock, Amit M. Oza

Research output: Contribution to journalArticle

Abstract

Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant. Improvements in trial design should be accompanied by improvements in available endpoints. Stakeholders need to come together to determine the best approach for research that ensures accountability and optimises the use of available resources.

Original languageEnglish (US)
Pages (from-to)e43-e52
JournalThe Lancet Oncology
Volume16
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Neoplasms
Social Responsibility
Therapeutics
Research
Patient Reported Outcome Measures

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Wilson, M. K., Collyar, D., Chingos, D. T., Friedlander, M., Ho, T. W., Karakasis, K., ... Oza, A. M. (2015). Outcomes and endpoints in cancer trials: Bridging the divide. The Lancet Oncology, 16(1), e43-e52. https://doi.org/10.1016/S1470-2045(14)70380-8

Outcomes and endpoints in cancer trials : Bridging the divide. / Wilson, Michelle K.; Collyar, Deborah; Chingos, Diana T.; Friedlander, Michael; Ho, Tony W.; Karakasis, Katherine; Kaye, Stan; Parmar, Mahesh K B; Sydes, Matthew R.; Tannock, Ian F.; Oza, Amit M.

In: The Lancet Oncology, Vol. 16, No. 1, 2015, p. e43-e52.

Research output: Contribution to journalArticle

Wilson, MK, Collyar, D, Chingos, DT, Friedlander, M, Ho, TW, Karakasis, K, Kaye, S, Parmar, MKB, Sydes, MR, Tannock, IF & Oza, AM 2015, 'Outcomes and endpoints in cancer trials: Bridging the divide', The Lancet Oncology, vol. 16, no. 1, pp. e43-e52. https://doi.org/10.1016/S1470-2045(14)70380-8
Wilson MK, Collyar D, Chingos DT, Friedlander M, Ho TW, Karakasis K et al. Outcomes and endpoints in cancer trials: Bridging the divide. The Lancet Oncology. 2015;16(1):e43-e52. https://doi.org/10.1016/S1470-2045(14)70380-8
Wilson, Michelle K. ; Collyar, Deborah ; Chingos, Diana T. ; Friedlander, Michael ; Ho, Tony W. ; Karakasis, Katherine ; Kaye, Stan ; Parmar, Mahesh K B ; Sydes, Matthew R. ; Tannock, Ian F. ; Oza, Amit M. / Outcomes and endpoints in cancer trials : Bridging the divide. In: The Lancet Oncology. 2015 ; Vol. 16, No. 1. pp. e43-e52.
@article{4ab0a75c042d43fba321fd89cf2b2711,
title = "Outcomes and endpoints in cancer trials: Bridging the divide",
abstract = "Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant. Improvements in trial design should be accompanied by improvements in available endpoints. Stakeholders need to come together to determine the best approach for research that ensures accountability and optimises the use of available resources.",
author = "Wilson, {Michelle K.} and Deborah Collyar and Chingos, {Diana T.} and Michael Friedlander and Ho, {Tony W.} and Katherine Karakasis and Stan Kaye and Parmar, {Mahesh K B} and Sydes, {Matthew R.} and Tannock, {Ian F.} and Oza, {Amit M.}",
year = "2015",
doi = "10.1016/S1470-2045(14)70380-8",
language = "English (US)",
volume = "16",
pages = "e43--e52",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Outcomes and endpoints in cancer trials

T2 - Bridging the divide

AU - Wilson, Michelle K.

AU - Collyar, Deborah

AU - Chingos, Diana T.

AU - Friedlander, Michael

AU - Ho, Tony W.

AU - Karakasis, Katherine

AU - Kaye, Stan

AU - Parmar, Mahesh K B

AU - Sydes, Matthew R.

AU - Tannock, Ian F.

AU - Oza, Amit M.

PY - 2015

Y1 - 2015

N2 - Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant. Improvements in trial design should be accompanied by improvements in available endpoints. Stakeholders need to come together to determine the best approach for research that ensures accountability and optimises the use of available resources.

AB - Cancer is not one disease. Outcomes and endpoints in trials should incorporate the therapeutic modality and cancer type because these factors affect clinician and patient expectations. In this Review, we discuss how to: define the importance of endpoints; make endpoints understandable to patients; improve the use of patient-reported outcomes; advance endpoints to parallel changes in trial design and therapeutic interventions; and integrate these improvements into trials and practice. Endpoints need to reflect benefit to patients, and show that changes in tumour size either in absolute terms (response and progression) or relative to control (progression) are clinically relevant. Improvements in trial design should be accompanied by improvements in available endpoints. Stakeholders need to come together to determine the best approach for research that ensures accountability and optimises the use of available resources.

UR - http://www.scopus.com/inward/record.url?scp=84924914921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924914921&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70380-8

DO - 10.1016/S1470-2045(14)70380-8

M3 - Article

C2 - 25638556

AN - SCOPUS:84924914921

VL - 16

SP - e43-e52

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -